// App-Quantinova.ai

BSH2020‐EP‐001 : Outcomes following treatment discontinuation in chronic myeloid leukaemia (CML): real‐world experience from three regional UK centres

Researchers

Presenter

  • F. Wandroo

Principal Investigators

  • M. Raghavan

  • J. Ewing

  • M. Kwok

  • Y. Hasan

  • S. Pancham

  • A. Shenouda

Medical Centers

  • Haematology, Sandwell and West Birmingham Hospital NHS Trust

  • University Hospitals Birmingham, Birmingham, UK

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Myelogenous Leukemia

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Interferon alpha

  • Nilotinib

  • dasatinib

  • Imatinib

  • IkT001

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved